ArticlePLoS neglected tropical diseases2025
Long-term outcomes of benznidazole treatment in chronic Chagas disease: A 27-year cohort study of parasitological cure and death in the Jequitinhonha Valley, Brazil.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human Histatin 5 Exerts Anti-Trypanosomal Activity AgainstInternational journal of molecular sciences · 2026Article
- Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation.Infectious disease reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundChagas disease (CD) is a neglected tropical infection prevalent in rural areas of Latin America. The etiological treatment is indicated for patients with both acute and chronic phases of CD, except in the most advanced clinical stage of the disease. However, there are still several divergences regarding the benefits of etiological treatment in chronic CD as far as the parasitological cure and survival/mortality outcomes. The present study aimed at verifying the impact of benznidazole (BZ) treatment on parasitological cure and death of patients with chronic CD at 9, 13, and 27 years post-treatment.
objectiveThis study aimed to verify the impact of BZ-treatment on parasitological cure and death of patients with chronic CD at 9, 13, and 27-year follow-up.
methodsA historical and prospective cohort of 42 patients with chronic CD, categorized as BZ-treated (BZ-T, n = 21) and Not-treated (NT, n = 21), were evaluated after 9, 13, and 27 years of follow-up, using parasitological tests (Hemoculture-HC, polymerase chain reaction-PCR, and quantitative real-time PCR-qPCR), conventional-CS (ELISA), and non-conventional-NCS (Chagas-Flow ATE) serology, employing three distinct cure criteria, one classical and two alternative. Survival analysis for death was determined by the Kaplan-Meier method.
resultsParasitological data (HC, PCR and qPCR) were negative in all patients (BZ-T and NT) at 27-year follow-up. The CS was negative in 75% and 23.1% of patients from BZ-T and NT, respectively. NCS had a higher negative rate (95%) than CS (23.1%) in BZ-T. The classic cure criterion demonstrated that 75% of BZ-T achieved a successful therapeutic outcome. Moreover, the use of the second and third alternative cure criteria revealed a higher proportion of cure in BZ-T (90%). The overall mortality over 27-year follow-up was 4.8% in BZ-T and 38.1% in NT. Kaplan-Meier survival curves for survival estimated 95% and 40% for BZ-T and NT patient groups.
conclusionsThe overall analysis demonstrated that BZ-T chronic CD patients yielded higher parasitological cure rates as well as increased survival over a 27-year follow-up. The Chagas-Flow ATE proved to be a valuable tool for monitoring therapeutic response and, together with parasitological and molecular parasitological methods, provided a more accurate cure criterion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.